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Summary
Uncertainty regarding pathogenic mechanisms has been a major impediment to effective prevention
and treatment forhuman neurologic diseases such as multiple sclerosis, tropical spastic paraparesis,
and AIDS demyelinating disease. Here, we implicate lymphotoxin (LT) (tumor necrosis factor
(3 [TNF-0]) and TNF-ci in experimental allergic encephalomyelitis (EAE), a murine model of
an autoimmune demyelinating disease. In this communication, we report that treatment ofrecipient
mice with an antibody that neutralizes IT and TNF-a prevents transfer of clone-mediated EAE .
LNC-8, a myelin basic protein-specific T cell line, produces high levels ofIT and TNF-ot after
activation by concanavalin A, antibody to theCD-3e component of the T cell receptor,or myelin
basic protein presented in the context of syngeneic spleen cells . LNC-8 cells transfer clinical signs
ofEAE . WhenLNC-8 recipient mice were also treated with TN3.19.12, a monoclonal antibody
that neutralizes IT and TNF-ci, the severity of the transferred EAE was reduced, while control
antibodies did not alter the disease . The effect of anti-LT/TNF-cx treatment was long lived and
has been sustained for 5 mo . These findings suggest that IT and TNF-ci and the T cells that
produce them play an important role in EAE.
I
t has been suggested that the cytokines lymphotoxin (LT)'
(TNF-a) and TNF-ot could contribute to pathogenesis in
several human neurologic diseases, including multiple scle-
rosis (MS) (1) and AIDS dementia (2) . If that were the case,
inhibition of the induction or activity of such cytokines might
alleviate the tissue damage and demyelination associated with
these diseases . In this study, we test the hypothesis that IT
and TNF-cx are involved in experimental allergic enceph-
alomyelitis (EAE), a murine model forMS, and demonstrate
that inhibition of their activity prevents transfer of clinical
signs of this paralytic disease.
IT and TNF-ci are genetically related cytokines with sev-
eral activities that could contribute to demyelinating diseases.
TNF-cx is produced by macrophages after stimulation with
LPS, whereas both IT and TNF-ci are released by T cells
activated by antigen or infection with some viruses, including
human T cell leukemia virus type I (HTLVI) (3, 4) . IT and
TNF-ot activities appear to be beneficial in defense against
tumors and virus-infected cells (3), and detrimental in their
' Abbreviations used in this paper . EAE, experimental allergic encephalo-
myelitis ; HTLV1, human T cell leukemia virus type I ; LT, lymphotoxin ;
MBP, myelin basic protein ; MS, multiple sclerosis.
association with cachexia (5) and (for TNF-a) in the patho-
genesis ofcerebral malaria (6) . Evidence has accumulated that
supports but does not yet prove a role for IT and TNF-ac
in certain neurologic diseases . One of the earliest descrip-
tions of IT was derived from a study of lymphocytes of rats
with EAE (7) . TNF-ct causes demyelination and death of
oligodendrocytes in vitro (8) . Further corroboration and a
suggestion for the biologic relevance of these observations
is indicated by the recent description ofTNF-ci inMS plaques
(9) . The high levels of IT produced by HTLVI-infected T
cell lines (10-12) is also consistent with an involvement of
IT in tropical spastic paraparesis, a neurologic disease associated
with infection with that human retrovirus .
In related studies (13, 14), we have presented circumstan-
tial evidence for a role ofIT in EAE . A series of myelin basic
protein (MBP-reactive) PL/J T cell clones had identical an-
tigen fine specificity andMHC restriction, used the sameTCR
V(3 gene (15), and produced Ilr2 in response to the encephalito-
genic peptide (amino acids 1-11) of MBP presented in the
context of H-2u . Despite these similarities, the clones varied
in their ability to transfer EAE, and this was positively cor-
related with the amount ofLT/TNF-cx cytotoxic activity and
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transferred EAE efficiently, as assessed by incidence of dis-
ease, severity of clinical signs, and day of onset, produced
high levels of cytotoxic factors (256 U) andmRNA for LT .
Those that did not transfer disease produced low or unde-
tectable levels (0-16 U) of cytotoxic activity and ITmRNA.
The correlation with TNF-a was not as clear. Most clones
that madeITmRNA also made TNF-amRNA . However,
one clone made high levels ofTNT-a mRNA, but did not
secrete cytotoxic material, and did not transfer disease partic-
ularly well . No correlation was found between IFN-'Y and
IL-2 production and encephalitogenicity .
In this communication, we present additional data that
support the hypothesis that IT and/or TNF-a are involved
in the pathogenesis ofEAE . These results obtained with the
SJL/J murine model ofEAE indicate that inhibition of IT
and TNF-a reduces the severity of disease symptoms trans-
ferred by a T cell line . One implication of these results is
that inhibition of these cytokines might alleviate clinical
signs in certain immunologically mediated human neurologic
diseases .
Materials and Methods
LNC 8 T Cell Line.
￿
LNC-8 was derived from the pophteal
lymph nodes of an SJL mouse immunized with porcine MBP.
LNC-8 was maintained with biweekly addition of human rIIr2
(Amgen Biologicals, Thousand Oaks, CA) and stimulated with
porcine MBP (101Lg/ml ; Calbiochem-Behring Corp., San Diego,
CA) and irradiated SJL splenocytes every other week .
Activation ofLT and TNF-a Production.
￿
LNC-8 cells (2 x
106/ml) were incubated in medium that contained 10% FCS alone,
or were supplemented with ConA (5 tug/ml), or 25 or 1001Ag/ml
porcine MBP and irradiated syngeneic SJL spleen cells . For stimu-
lation with anti-CD3, LNC-8 cells were added as above to tissue
culture flasks that had been incubated overnight with anti-CD3
e antibody YCD3-1 (16), then rinsed twice with PBS. Culture su-
pernatants were collected from activated cells at various times be-
tween 8 and 48 h and tested for cytotoxic activity against WEHI
164 cells .
Biologic AssayforLT andTNEa .
￿
Fordetermination ofLT/TNF
units, a sensitive WEHI 164 subline obtained from Edward Lat-
time (Memorial Sloan-Kettering, New York) was used as a target .
WEHI 164 cells (5 x 103/well) were set up in 96-well tissue cul-
ture plates in RPMI 1640 with 10% FCS, 1% nonessential amino
acids, 1% essential amino acids, 1% sodium pyruvate in dilutions
oftest and control samples in a volume of100 pl . After 44 h,WEHI
164 survival was evaluated by the cells' 4-h uptake ofMTT (17),
which was then acidified with 150 p1 0.04M HCL in isopropenol.
The plate was read on aVmax plate reader at 470 nm with a 650-
nm reference standard . Units were calculated as the highest dilu-
tion causing50% cytotoxicity . Percent cytotoxicity was calculated
as : 100x (1.00 - OD of sample wells)/OD of control wells.
Neutralization ofLT/TNFce Biologic Activity .
￿
Supernatants con-
taining WEHI 164 cytotoxic activity were diluted to 64 U and
incubated with TN3.19.12 obtained from Dr. Robert Schreiber
(Washington University, St . Louis, MO) . This hamster mAb has
been previously demonstrated to neutralize both LT and TNF-a
(18). After incubation for 1 h at 37°C, the supernatants were added
to WEHI 164 cells and assayed as above.
Northern Blot Analysis. Total RNA was obtained by the
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guanidinium thiocyanate cesium chloride method (19) from un-
stimulated murine L cells, and from SJL splenocytes and LNC-8
cells after activation. RNA (20 wg) was subjected to electropho-
resis in a 0.66M formaldehyde/MOPS 1% agarose gel, transferred
to Gene Screen Plus (New England Nuclear, Boston, MA), and
hybridized with TNF-acDNA (20) (a generous gift from Dr. Bruce
Beutler, University of Texas Southwestern Medical School), LT
cDNA (21), or (3-actincDNA (22) (a generous gift from Dr. D.
Cleveland, Johns Hopkins University Medical School) labeled by
the random primer method (23) . The filters were washed twice
for 15 min at 55°C with 0.2x SSC and 0.1% SDS, and exposed
to XAR film with intensifying screens .at -70°C.
Transfer and Evaluation ofEAE .
￿
LNC-8 cells were stimulated
withMBP (10 pg/ml) and spleen cells for 3 d . The cells were then
exposed to 2 U/ml 11,2 for 1 d . After that time, 7.5-12 x 106
LNC-8 cells were injected intraperitoneally or intravenously as in-
dicated in individual experiments. The mice were divided into groups
and, 48 h later, injected with PBS, hamster control antibody L2D39,
rat anti-IL4 antibody 11B11 (24), or hamster anti-LT/TNF-a anti-
body TN3.19.12 (18) . Mice were evaluated for clinical signs ofEAE
daily for at least 21 d after injection of cells. The study was done
in a blinded fashion . That is, the observer was unaware ofthe pro-
tocol . The clinical scale was as follows : 0 = normal, 1 = tail limp-
ness, 2 = paraparesis with a clumsy gait, 3 = hind limb paralysis,
4 = hind and fore limb paralysis, 5 = death .
FRCS Analysis.
￿
LNC-8 cells were analyzed for V0 gene usage
12 d after being stimulated with irradiated splenocytes and MBP.
Cells were incubated with supernatant from KJ23a, a generous gift
ofDrs . John Kapplerand Phillippa Marrack (NationalJewish Center,
Denver, CO), or a control supernatant and stained with fluorescein-
conjugated goat anti-mouse antibody. Binding was evaluated with
a FACS analyzer (Becton Dickinson &Co., Mountain View, CA) .
Results
Characteristics ofLNC-8 Cells.
￿
The IIr2-dependent T cell
line LNC-8 used in the present studies to transfer EAE
proliferates in response to MBP in the context of H-2' . It
proliferates to all three major pepsin-digested fractions ofMBP
(data not shown) . One of these fractions includes the pep-
tide, which is encephalitogenic for SJL/J mice, that lies in
the COON-terminal end of theMBP molecule (25) . We have
found by FACS analysis that -50% of LNC-8 T cells stain
with KJ23a, an antibody that reacts with the Va17a gene
product of the TCR (Fig. 1) . This TCR gene usage is con-
sistent with the observation that V017a and at least one other
as yet undefined Vii gene are utilized by encephalitogenic
SJL clones (26) .
LT andTNF-a Production byLNC-8 Cells.
￿
WhenLNC-8
cells are stimulated by Con A, they produce mRNA for
several cytokines, including IFN--y and GM-CSF (data not
shown) and IT and TNF-ca (Fig. 2) . Of particular interest
is the fact that in theRNA samples from stimulated LNC-8
cells IT mRNA appeared to be at higher abundance than
TNF-tx mRNA, and that the T cell line made considerably
more IT and TNFmRNA than do Con A-activated spleen
cells . There are actually several molecular species ofLNC-8
RNA that hybridize with both the IT and TNF-a cDNA
probes. One high molecular weight species (-3 kb) hybrid-
izes with both probes and could represent an IT pro-
moter-regulated transcript driven through the entire 6-kbLog Fluorescence
a
Figure 1.
￿
TheLNC-8 cell line includes aV017a' population . LNC-8
cells were analyzed for V)317a usage 12 d after last being stimulated with
irradiated SJL splenocytes and MBP . Cells were incubated with superna-
tant KJ23a (antiV/317a) or with control supernatant, washed, and stained
with fluorescein-conjugated goat anti-mouse antibody. Binding was ana-
lyzed on aFRCS analyzer (Becton Dickinson& Co .) . (A) Control super-
natant ; (B) antiVO17a .
TNF-a/(3 gene complex within theMHC on mouse chro-
mosome 17 (27, 28) .
Culture supernatants from LNC-8 cells activated by sev-
eral different methods contained cytotoxic activity against
WEHI 164 cells, a target for both IT and TNF-a (Table 1) .
Because the bioassay does not distinguish between the two
cytokines, the results are expressed as LT/TNF-a activity.
LNC-8 cells did not secrete LT/TNF unless activated . They
' LNC-8 cells were incubatd for 8 h in growth media plus 10% FCS .
Conditions of stimulation were as indicated in Materials and Methods .
Exp . 1, MBP concentration was 25 lAg/ml; Exp. 2, MBP was 100 /~g/ml .
t LT/TNF units were determined by cytotoxic effect against WEHI 164
cells .
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secreted high levels of LT/TNF after stimulation with
nonspecific mitogens, stimulation through the TCR by an
anti-CD3 antibody YCD3-1 (16), or by MBP presented by
syngeneic spleen cells. The amount of cytotoxic activity in
the culture supernatants increased over time of stimulation,
particularly when LNC-8 cells were activated withMBP and
spleen cells . In experiment 1 (Table 1), the amount of cyto-
toxic activity in supernatants after antigen stimulation was
256U at 8 h,1,024 U at 24 h, and 2,048 U at 48 h . Northern
blots of RNA prepared from LNC 8 cells activated under
all conditions of Table 1 were positive for both IT and
TNF-at mRNA, with usually higher accumulations of IT
mRNA, as in Fig. 2 . Though it is not possible to distin-
guish betweenIT andTNF-a in the biologic assay, it is likely
that theWEHI 164 killing in the experiments reported here
is due to both cytokines since the activated LNC-8 cells made
both mRNAs . In other studies, we have observed that the
kinetics ofIT and TNF-a mRNA production can vary in
individualT cell clones, and the cytotoxic activity attributable
to the individual cytokines varies with activation time .
Neutralization ofLNC-8 Cytotoxic Activity byAnti-LT/TNEa
Antibody . In a previous publication (18), we described a ham-
ster mAb, TN3.19.12, that reacts both with IT and TNF-a
derived from supernatants ofT cell clones and with TNF-a
derived from macrophage culture supernatants . This antibody
also neutralized the cytotoxic activity secretedbyLNC-8 cells,
indicating that the WEHI 164 killing activity is due to IT
and/or TNF-cx . TN3.19.12 anti-LT/TNF-at antibody com-
pletely neutralizedWEHI 164 cytotoxic activity of superna-
tants obtained after all methods ofactivation ofLNC-8 cells,
including antigen plus spleen cells (Fig. 3), Con A, and anti-
CD3 antibody.
Inhibition of Transfer ofEAE by LNC-8 by Treatment ofRe-
cipient Mice with Anti-LT/TNF-a Antibody. LNC-8 cells are
potent mediators ofEAE . When 1.5 x 107 cells are injected
Figure 2. LNC-8 cells produce TNF-oa and LT (TNF-0) mRNA.
Northern blot analysis of total RNA (20,ug) obtained from unstimulated
murine L cells and from SJL splenocytes and LNC-8 cells after 8-h ex-
posure to 5 Etg/ml Con A, hybridized with TNF-acDNA (A), LTcDNA
(B), or /3-actin cDNA (C), and exposed with intensifying screens for
15 h (A), 2.5 h (B), or 30 min (C) to XAR5 film .
Relative
Cell _
Number
100 101 102 103
Log Fluorescence
Relative
Cell
Number
V 1 -1 --1
100 101 102 103
Table 1.
Exp .
LNC-8 Cells Produce LT/TNF
Stimulating agent"
After Activation
LT/TNFt
1 - 0
MBP/SC 256
Con A 32,000
2 - 2
MBP/SC 512
Anti-CD3 25,600LT / TNFcx UNITS
Figure 3.
￿
Hamster anti-LT/TNF-a mAb TN3.19.12 neutralizes cyto-
toxic activity in supernatants obtained from LNC-8 cells. Supernatant ob-
tained from LNC-8 cells after incubation for 24 h with MBP and irradi-
ated SJL spleen cells contained 1,024U LT/TNF-a . The supernatant was
diluted to 64 U and incubated in complete medium (0) or 850 ng
TN3.19.12(M) for 1 h at 37°C, and thenadded toWEHI 164 cells. Cyto-
toxicity was evaluated at 44 h .
intraperitoneally or intravenously, -90% of the recipients
develop clinical signs of severe EAE, usually within 7 d. Ap-
proximately 75% of the mice die. When lower numbers of
LNC-8 cells are injected, the disease is not as debilitating,
resulting in somewhat less severe clinical signs, fewer deaths,
and delayed onset .
When mice that received LNC-8 cells were treated with
the anti-LT/TNF-ac mAbTN3.19.12, symptoms and severity
Table 2 .
￿
Treatment of Mice with Anti-LT/TNF-a Antibody Reduces EAE Severity
Antibody treatment
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ofEAE were alleviated . In five different experiments (Table
2, protocol A), groups of four or five mice were injected with
7.5-9 x 106 LNC-8 cells intraperitoneally, and then treated
48 h later with a single intraperitoneal injection of 300 ug
TN3.19.12, PBS, or a control hamster mAb, L2D39. Mice
were evaluated daily for clinical signs ofEAE for 3 wk . Treat-
ment with anti-LT/TNF-a resulted in a dramatic reduction
in the severity of clinical symptoms (Table 2) . The effect of
anti-LT/TNF-a treatment on the course of the disease is most
apparent when the average disease scores ofTN3.19.12-treated
and control groups are compared . The average highest group
score of mice that received 7.5-9 x 106 LNC-8 cells and
PBS or the control hamster monoclonal L21339 was 2.6 or
2 .2, respectively, while the average highest group score of
mice that received TN3.19.12 was 0.9, which is actually below
clinically detectable disease (Table 2) . These results are highly
significant (p < 0.001) when TN3.19.12-treated mice were
compared with PBS-treated mice by student's t test . L2D39
control (hamster antibody) treatment did not significantly
affect the progression of the disease (p < 0.252) . Those mice
that did develop disease in the group receiving cells and
TN3.19.12 developed clinical signs slightly later than did the
control mice, and this disease was less severe. Those TN3.19.12-
treated mice that did develop clinical signs had an average
maximum disease score of 2, compared with 3.7 for mice
that were treated with control antibody and developed clin-
ical signs. In an additional experiment (Table 2, protocol B),
1.2 x 107 cells were injected intravenously in groups of 9
or 10 mice. In this experiment, a higher dose (1 mg) of anti-
LT/TNF-cx and a different control antibody (111311, anti-
IL-4) were used. The more severe disease that was induced with
p < 0.001 when 0.3 mg TN3.19.12 mice are compared with PBS-injected mice. p< 0.2521 when L2D39 mice are compared with PBS-injected
mice . p < 0.00035 when 1 mg TN3.19.12-treated mice are compared with PBS mice . Protocol A was a summary of five separate experiments with
four to five mice per group. Protocol B was one experiment .
` Average day of onset ± SEM of clinical signs ofEAE.
Average disease per group ± SEM. Mice were graded on a scale of 0-5, as indicated in Materials and Methods .
Protocol Amount Antibody n Antibody specificity Day of onset" Average disease#
A (7-9 x 106 LNC-8
cells i .p .)
mg
- PBS 10 - 6.2 ± 0.3 2.6 ± 0.4
0.3 L2D39 15 - 7.8 ± 1 .0 2.2 ± 0.7
0.3 TN3 .19.12 21 Anti-LT/TNF-a 8.6 ± 0.7 0.9 ± 0.3
B (1.2 x 107 LNC-8
cells i .v .) - PBS 9 - 7.1 ± 0.9 3.9 ± 0.6
1 111311 4 Anti-IL-4 7.5 ± 0.5 3.3 ± 1.6
1 TN3 .19.12 10 Anti-LT/TNF-a 7.0 ± 0.0 0.2 ± 0.1Figure 4.
￿
Anti-LT/TNF-a antibody treatment alleviates histologic signs of EAE . Analysis of spinal cord stained with hematoxylin and eosin. (a)
Tissue section 9 d after injection of 9 x 106 LNC-8 cells and 7 d after PBS. Note perivascular infiltrate. (b) Tissue section 9 d after injection of 9
x 106 'LNC-8 cells and 7 d after injection of 300 jug TN3.19.12 . Note absence of infiltrate.
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￿
The alleviation ofclinical signs of.EAE inducedby treatment
with anti-LT/TNF-a antibody is persistent. Mice were injected with 7.5
x 106 LNC-8 cells intraperitoneally. 2 dlater, one group of mice received
PBS (+), and one group received 300 Ag anti-LT/TNF-ca antibody
TN3.19.12 (Q). Mice were evaluated for clinical signs of EAE daily for
3 wk, and then three times a week for an additional 4 mo.
this dose of cells was dramatically inhibited with one injec-
tion of anti-LT/TNF-or. As indicated in Table 2, the average
disease score was 3.9 for the PBS-treated group; 3.3 for the
anti-Ilr4-treated group, and 0.2 for the anti-LTTNF-a treated
group (the latter score again below clinically detectable dis-
ease). The incidence of disease was also reduced from 89%
in the PBS treated group to 20% in the anti-LT/TNFLu group.
The highest score of disease was 1 in this group.
Histological evaluation of mice that received LNC-8 cells
and TN3.19.12 that remained clinically normal revealed that
some of these mice showed no evidence of cellular infiltra-
tion or abnormality, whileothers showed meningeal infiltra-
tion and mild perivascular cuffing. All mice from the group
that received LNC-8 cells and control antibodies or PBS that
were examined had histologic signs of cuffing and infiltra-
tion consistent with their clinical signs (Fig. 4) .
The inhibition oftransfer of EAE by treatment with anti-
LT/TNF-a antibody was long lived. Several groups of mice
were observed for 2-3 mo. None developed disease if it bad
not occurred by day 12. In the representative experiment
depicted in Fig. 5, mice were observed for 5 mo afterreceipt
of 7.5 x 106 LNC-8 cells and antibody or PBS. The only
mouse in the group of five that received both cells and
TN3 .19.12 to develop clinical signs had a limp tail (grade
1) from day 7 through day 26 and then recovered. Neither
it nor any of the other mice in the antibody-treated group
developed any further symptoms. In the control group (five
mice) that received cells and PBS, four developed clinical signs,
one ofthese died on day 12, and the others eventually recovered.
Discussion
The data presented here implicate IT and TNF-a in the
passively transferred autoimmune neurological disease EAE.
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We demonstrate that a MBP-specific T cell line produces IT
and TNF-a cytotoxic activity after activation with any of
several different agents. The biologic activity is neutralized
by an anti-LT/TNF-a antibody. The ability of LNC-8 cells
to transfer EAE into naive mice is prevented if those mice
are treated with the anti-LT/TNF-a antibody, but not with
control antibodies. The use of an antibody that completely
neutralizes both IT and TNF-a may be important since both
cytokines are made by LNC-8 cellsafteractivation with MBP,
the relevant neuroantigen in this model of EAE. Absolute
certainty that only one or the other cytokine is involved will
only come with mAbs that distinguish between the murine
forms. These are not yet available, and the polyclonal anti-
bodies that we have tested in vitro are variable and inconsis-
tent. It is particularly relevant to the human situation that
we were able to inhibit the transfer of EAE by a cell line
that contains at least two T cell populations that utilize
different TCRO genes. This suggests that these experiments
may be broadly relevant to the human situation where, even
though particular TCR(3 genes may be preferentially uti-
lized by siblings with MS (29), the actual gene(s) have not
yet been identified. It is likely that the number of TCR(3
genes utilized in this disease by the highly polymorphic human
population is limited, but it is certainly greater than one.
The studies reported here are the first antibody neutraliza-
tion experiments of EAE that provide insight into the iden-
tity ofthe mediators of the disease. The extent ofprevention
of transfer of EAE was dependent on the dose of anti-LT/
TNF-a antibody used, and these doses (0.3 or 1 mg) were
comparable with or less than those used in experiments with
other antibodies to inhibit transfer or development of EAE.
Sriram et al. (30) used three injections of 3 mg of anti-I-A
antibodies on successive days before and after injection ofen-
cephalitogenic T cell clones to inhibit transfer ofEAE. Urban
et al. (31) injected 5001.Ag antiV08 antibody to prevent de-
velopment ofEAE, and Acha Orbea et al. (15) used two 100-
ttg injections of anti-VO8 antibody to inhibit T cell transfer
ofdisease. In the previous experiments, the design was based
on preventing T cell activation (30) or a major component
of the T cell repertoire (15, 31). The experiments reported
here represent a different approach to EAE; that is, TN3.19.12
inhibits the activity of mediators that are produced in vivo
after stimulation of an antigen-specificpopulationofeffector
T cells.
The mechanism by which the anti-LT/TNF-a antibody
prevents the transfer ofEAE is under investigation. It is pos-
sible that the antibody inhibits the disease in part bybinding
to and eliminating TNF-bearing T cells. This possibility is
raised by the identification of membrane-bound TNF on a
murine CTL clone with a polyclonal rabbit anti TNF anti-
body (32), and the demonstration of TNF/cachectin on acti-
vated normal human T cells with an anti-TNF mAb (33).
We do not believe that this is the most likely explanation
for our results, because we have not been able to detect mem-
brane TNF from macrophage lysates with TN3.19.12 (18),
though we were able to detect a high molecular weight spe-
cies from membranes ofPU.5.1.8 with a polyclonal antibody
(T. James and N. Ruddle, unpublished results) . Moreover,we have not been able to demonstrate surface staining by FACS
with TN3.19.12 ofLNC-8 cells treated identically to those
used in the transfer studies. Maximum staining of 106 cells
treated with 1, 10, or 100 pg/ml TN3.19.12 and a rabbit
anti-hamster fluoresceinated antibody was 3.1% ; under the
same conditions, 94% of the cells were positive by anti-CD3 .
Because the concentration of TN3.19.12 antibody used in
FACS experiments was comparable with that used in the in
vivo experiments (i.e., 300 pg/7 x 106 cells), we believe it
is unlikely that elimination ofTNF-bearing cells is the mech-
anism . Nevertheless, this possibility exists and is under in-
vestigation in in vivo experiments with labeled cells . Histo-
logical analysis of tissue from mice that have received LNC-8
cells andTN3.19.12 has revealed that some treated, clinically
normal mice had minimal evidence of cellular infiltrates, while
others did not . Thus, the antibody may inhibit transfer at
various stages by inhibiting several different activities of the
IT and TNF-a secreted byLNC-8 cells . These activities in-
volve a number of effects relevant to the pathogenesis ofEAE,
including an increase inMHC determinants on endothelial
cells (34), an alteration ofcentral nervous system permeability,
and an influx of inflammatory cells through an increase in
cell adhesion molecules on the endothelium (34) or astro-
cytes (35) . Cytokines produced by these inflammatory cells
may also directly affect the myelin sheath and influence via-
bility ofoligodendrocytes (8) . TN3.19.12 antibody could in-
hibit any of these activities by directly neutralizing secreted
IT and TNF-a . Further insight into these questions will de-
rive from experiments underway designed to reverse estab-
lished disease . Whatever the mechanism(s) by which this an-
tibody inhibits transfer ofEAE, this study demonstrates that
inhibition of IT and TNF-ct biologic activity prevents transfer
ofthe symptoms ofa severe an often fatal neurologic disease.
These studies suggest a role for these cytokines or cells that
express them in some neurologic diseases. If the transfer of
disease in the EAE model is inhibited through inhibitingIT
or TNF-ot activity, the studies point the way for the devel-
opment ofTNF antagonists in such disease. The recent cloning
of a receptor for IT and TNF-ot (36, 37) elicits cautious op-
timism regarding feasibility of therapy for cytokine-mediated
neurologic disease.
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